Downregulation of Right Ventricular Phosphodiesterase PDE-3 A mRNA and Protein before the Development of Canine Heart Failure

Cell Biochemistry and Biophysics

Volumn 29, Issue 1-2, 1998, Pages 67-88

  Smith, Carolyn J ^a   He, Jingzhi ^a   Ricketts, Sidonnie G ^a   Ding, Jia Zhen ^b   Moggio, Richard A ^b   Hintze, Thomas H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; MEMBRANE PROTEIN; MESSENGER RNA; PHOSPHODIESTERASE III;

ANIMAL; ARTICLE; CONGESTIVE HEART FAILURE; CYTOSOL; DISEASE MODEL; DOG; DOWN REGULATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE; INTRACELLULAR MEMBRANE; METABOLISM; MICROSOME; NORTHERN BLOTTING; PATHOPHYSIOLOGY; WESTERN BLOTTING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CYTOSOL; DISEASE MODELS, ANIMAL; DOGS; DOWN-REGULATION; GENE EXPRESSION REGULATION; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; INTRACELLULAR MEMBRANES; MEMBRANE PROTEINS; MICROSOMES; RNA, MESSENGER; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 0031615987     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02737829     Document Type: Article

References (39)

1. Meacci, E., Taira, M., Moos, M., Jr., Smith, C. J., Movsesian, M. A., Degerman, E., Belfrage, P., and Manganiello, V. (1992) Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc. Natl. Acad. Sci. USA 89, 3721-3725.
2. Taira, M., Hockman, S. C., Calvo, J. C., Belfrage, P., and Manganiello, V. C. (1993) Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J. Biol. Chem. 268, 18,573-18,579.
3. Reinhardt, R. R., Chin, E., Zhou, J., Taira, M., Murata, T., Manganiello, V. C., and Bondy, C. A. (1995) Distinctive anatomical patterns of gene expression for cGMP- inhibited cyclic nucleotide phosphodiesterases. J. Clin. Invest. 95, 1528-1538.
4. m, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem. Biophys. Res. Commun. 190, 516-521.
5. Kasuya, J., Goko, H., and Fujita-Yamaguchi, Y. (1995) Multiple transcripts for the human cardiac form of the cGMP-inhibited cAMP phosphodiesterase. J. Biol. Chem. 270, 14,305-14,312.
6. Kauffman, R. F., Crowe, V. G., Utterback, B. G., and Robertson, D. W. (1986) LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol. Pharmacol. 30, 609-616.
7. Pillai, R., Fluckiger Staub, S., and Colicelli, J. (1994) Mutational mapping of kinetic and pharmacological properties of a human cardiac cAMP phosphodiesterase. J. Biol. Chem. 269, 30,676-30,681.
8. Weishaar, R. E., Kobylarz-Singer, D. C., Steffen, R. P., and Kaplan, H. R. (1987) Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ. Res. 61, 539-547.
9. Movsesian, M. A., Komas, N., Krall, J., and Manganiello, V. C. (1996) Expression and activity of Low Km, cGMP-inhibited cAMP phosphodiesterase in cardiac and skeletal muscle. Biochem. Biophys. Res. Commun. 225, 1058-1062.
10. Degerman, E., Belfrage, P., and Manganiello, V. C. (1996) cGMP-inhibited phosphodiesterases (PDE-3 gene family). Biochem. Soc. Trans. 24, 1010-1013.
11. Packer, M., Carver, J. R., Rodeheffer, R. J., Ivanhoe, R. J., DiBianco, R., Zeldis, S. M., Hendrix, G. H., Bommer, W. J., Elkayam, U., Kukin, M. L., Mallis, G. I., Sollano, J. A., Shannon, J., Tandon, P. K., and DeMets, D. L. (1989) Effects of oral milrinone on mortality in severe chronic heart failure. N. Engl. J. Med. 325, 1468-1475.
12. Feldman, A. M., Bristow, M. R., Parmley, W. W., Carson, P. E., Pepaine, C. J., Gilbert, E. M., Strobeck, J. E., Hendrix, G. H., Powers, E. R., Bain, R. P., and White, B. G. (1993) Effects of vesnarinone on morbidity and mortality in patients with heart failure. N. Engl. J. Med. 329, 149-155.
13. Nony, P., Boissel, J.-P., Lievre, M., Leizorovicz, A., Haugh, M. C., Fareh, S., and de Breyne, B. (1994) Evalulation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur. J. Clin. Pharm. 46, 191-196.
14. Gilbert, E. M., Hershberger, R. E., Wiechmann, R. J., Movsesian, M. A., and Bristow, M. R. (1995) Pharmacologic and hemodynamic effects of combined β-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest 108, 1524-1532.
15. Feldman, M. D., Copelas, L., Gwathmey, J. K., Phillips, P., Warren, S. E., Schoen, F. J., Grossman, W., and Morgan, J. P. (1987) Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with endstage heart failure. Circulation 75, 331-339.
16. von der Leyen, H., Mende, U., Meyer, W., Neumann, J., Nose, M., Schmitz, W., Scholz, H., Starbatty, J., Stein, B., Wenzlaff, H., Doring, V., Kalmar, P., and Haverich, A. (1991) Mechanism underlying the reduced positive inotropic effects of phosphodiesterase inhibitors pimobendan, adibendan and saterinone in failing as compared to non-failing human cardiac muscle preparations. Naunyn-Schmiedeberg's Arch. Pharmacol. 344, 90-100.
17. Perreault, C. L., Shannon, R. P., Komamura, K., Vatner, S. F., and Morgan, J. P. (1990) Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J. Clin. Invest. 89, 932-938.
18. m cyclic nucleotide phosphodiesterase isozymes in human cardiac muscle from normal and cardiomyopathic subjects. Second Messengers and Phosphoproteins 13, 13-25.
19. Movsesian, M. A., Smith, C. J., Krall, J., Bristow, M. R., and Manganiello, V. C. (1991) Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. J. Clin. Invest. 88, 15-19.
20. Smith, C. J., Vasta, V., Degerman, E., Belfrage, P., and Manganiello, V. C. (1991) Hormone-sensitive cyclic GMP-inhibited cyclic AMP phosphodiesterase in rat adipocytes. Regulation of insulin- and cAMP-dependent activation by phosphorylation. J. Biol. Chem. 266, 13,385-13,390.
21. Macphee, C. H., Reifsnyder, D. H., Moore, T. A., Lerea, K. M., and Beavo, J. A. (1988) Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets. J. Biol. Chem. 263, 10,353-10,358.
22. Rascon, A., Lindgren, S., Stavenow, L., Belfrage, P., Andersson, K. E., Manganiello, V. C., and Degerman, E. (1992) Purification and properties of the cGMP-inhibited cAMP phosphodiesterase from bovine aortic smooth muscle. Biochim. Biophys. Acta 1134, 149-156.
23. Leroy, M.-J., Degerman, E., Taira, M., Murata, T., Wang, L. H., Movsesian, M. A., Meacci, E., and Manganiello, V. C. (1996) Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry 35, 10,194-10,202.
24. Smith, C. J., Huang, R., Sun, D., Ricketts, S., Hoegler, C., Ding, J.-Z., Moggio, R. A., and Hintze, T. H. (1997) Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A. Circulation 96(9), in press.
25. Degerman, E., Moos, M., Jr., Rascon, A., Vasta, V., Meacci, E., Smith, C. J., Lindgren, S., Andersson, K. E., Belfrage, P., and Manganiello, V. (1994) Single-step affinity purification, partial structure and properties of human platelet cGMP inhibited cAMP phosphodiesterase. Biochim. Biophys. Acta 1205, 189-198.
26. Smith, C. J., Sun, D., Hoegler, C., Roth, B. S., Zhang, X., Zhao, G., Xu, X., Kobari, Y., Pritchard Jr., K., Sessa, W. C., and Hintze, T. H. (1996) Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ. Res. 78, 58-64.
27. Zhao, G., Shen, W., Xu, X., Ochoa, M., Bernstein, R., and Hintze, T. H. (1995) Selective impairment of vagally mediated, nitric oxide-dependent coronary vasodilation in conscious dogs after pacing-induced heart failure. Circulation 91, 2655-2663.
28. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18, 5294-5299.
29. Liu, Y., Cignola, E., Cheng, W., Kajstura, J., Olivetti, G., Hintze, T. H., and Anversa, P. (1995) Myocyte nuclear mitotic division and programmed cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. Lab. Invest. 73, 771-787.
30. Sibbald, W. J. and Driedger, A. A. (1983) Right ventricular function in acute disease states: pathophysiologic considerations. Crit. Care Med. 11, 339-345.
31. Levine, B., Kalman, J., Meyer, L., and Packer, M. (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236-241.
32. Perreault, C. L., Shannon, R. P., Shen, Y., Vatner, S. F., and Morgan, J. P. (1994) Excitation-contraction coupling in isolated myocardium from dogs with compensated left ventricular hypertrophy. Am. J. Physiol. 266, H2436-H2442.
33. Araki, S., Uematsu, T., Nagashima, S., Matsuzaki, T., Gotanda, K., Ochiai, H., Hashimoto, H., and Nakashima, M. (1997) Cardiac and hemodynamic effects of TZC-5665, a novel pyridazinone derivative, and its metabolite in humans and dogs. Gen. Pharmacol. 28, 545-553.
34. Wagner, R. S., Smith, C. J., Taylor, A. M., and Rhoades, R. A. (1997) Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J. Pharmacol. Exp. Ther. 282, 1650-1657.
35. Givertz, M. M., Hare, J. M., Loh, E., Gauthier, D. F., and Colucci, W. S. (1996) Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. J. Am. Coll. Cardiol. 28, 1775-1780.
36. Matsui, S., Matsumori, A., Matoba, Y., Uchida, A., and Sasayama, S. (1994) Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis-α production. J. Clin. Invest. 94, 1212-1217.
37. m adenosine 3′,5′-monophosphate phosphodiesterase from human placental cytosolic fractions. Endocrinology 130, 3265-3274.
38. Manganiello, V. C., Degerman, E., Smith, C. J., Vasta, V., Tornqvist, H., and Belfrage, P. (1992) Mechanisms for activation of the rat adipocyte particulate cyclic-GMP-inhibited cyclic AMP phosphodiesterase and its importance in the antilipolytic action of insulin. Adv. Second Messengers and Phosphoproteins Res. 25, 147-164.
39. Tang, K. M., Jang, E. K., and Haslam, R. J. (1997) Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets. Biochem. J. 323, 217-224.